Skip to main content

Table 1 Patient Characteristics: Frontline Treatment with R-CVP and R-CHOP

From: R-CHOP versus R-CVP in the treatment of follicular lymphoma: a meta-analysis and critical appraisal of current literature

Variable

(N; %)

R-CHOP

N = 223

Hiddemann et al [5]

R-CVP

N = 162

Marcus et al [7]

Total

N = 385

P-value

Sex

M:88; 39.5%

F: 135; 60.5%

M: 88; 54.3%

F: 74; 45.7%

M: 176; 45.7%

F: 209; 54.3%

.004

Age>60

82; 36.8%

41; 25.3%

123; 31.9%

.017

ECOG>1

16; 7.2%

4;2.5%

20; 5.2%

.040

B-symptoms

80; 35.9%

65; 40.1%

145; 37.7%

.396

Marrow involvement

136; 61.0%

103; 63.6%

239; 62.1%

.605

IPI> 2

42; 18.8%

21; 13.0%

63; 16.4%

.212

Stage

I/II: 0; 0%

III/IV: 223; 100%

I/II: 2; 1.2%

III/IV: 160; 98.8%

I/II: 2; 0.5%

III/IV: 383; 99.5%

.342

Elevetaed LDH

51; 22.9%

39; 24.1%

90; 23.4%

.783